Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion via NF-κB inhibition

Resistance to chemotherapy is a long-standing problem in the management of cancer, and cancer stem cells are regarded as the main source of this resistance. This study aimed to investigate metallothionein (MT)-1G involvement in the regulation of cancer stemness and provide a strategy to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC). Methods: MT1G was identified as a critical factor related with gemcitabine resistance in PDAC cells by mRNA microarray. Its effects on PDAC stemness were evaluated through sphere formation and tumorigenicity. LC-MS/MS analysis of conditional medium revealed that activin A, a NF-κB target, was a major protein secreted from gemcitabine resistant PDAC cells. Both loss-of-function and gain-of-function approaches were used to validate that MT1G inhibited NF-κB-activin A pathway. Orthotopic pancreatic tumor model was employed to explore the effects on gemcitabine resistance with recombinant follistatin to block activin A. Results: Downregulation of MT1G due to hypermethylation of its promoter is related with pancreatic cancer stemness. Secretome analysis revealed that activin A, a NF-κB target, was highly secreted by drug resistant cells. It promotes pancreatic cancer stemness in Smad4-dependent or independent manners. Mechanistically, MT1G negatively regulates NF-κB signaling and promotes the degradation of NF-κB p65 subunit by enhancing the expression of E3 ligase TRAF7. Blockade of activin A signaling with follistatin could overcome gemcitabine resistance. Conclusions: MT1G suppresses PDAC stemness by limiting activin A secretion via NF-κB inhibition. The blockade of the activin A signaling with follistatin may provide a promising therapeutic strategy for overcoming gemcitabine resistance in PDAC.

[1]  Xianjun Yu,et al.  A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance , 2020, Theranostics.

[2]  V. Adam,et al.  Metallothionein isoforms as double agents - Their roles in carcinogenesis, cancer progression and chemoresistance. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[3]  Y. Mei,et al.  lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCFβ-TRCP-Mediated Degradation of NRF2 in Pancreatic Cancer , 2020, Molecular therapy. Nucleic acids.

[4]  Shusen Yang,et al.  The E3 ubiquitin ligase RNF182 inhibits TLR‐triggered cytokine production through promoting p65 ubiquitination and degradation , 2019, FEBS letters.

[5]  G. Xanthou,et al.  Activin-A in the regulation of immunity in health and disease. , 2019, Journal of autoimmunity.

[6]  W. Gong,et al.  Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A , 2018, Clinical Cancer Research.

[7]  J. Lang,et al.  The roles of metallothioneins in carcinogenesis , 2018, Journal of Hematology & Oncology.

[8]  Jordan F Hastings,et al.  Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy , 2018, Science Translational Medicine.

[9]  Yuntao Guo,et al.  Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway , 2018, Theranostics.

[10]  T. Ochiya,et al.  Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells , 2018, Cell Death & Disease.

[11]  H. Rupasinghe,et al.  Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.

[12]  I. Gupta,et al.  Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis , 2018, Front. Cell Dev. Biol..

[13]  Bechien U. Wu,et al.  Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. , 2018, Journal of gastrointestinal oncology.

[14]  Huanjie Yang,et al.  Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells , 2017, Cell Death & Disease.

[15]  M. Bianchini,et al.  Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells , 2017, Oncology reports.

[16]  W. Jiang,et al.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours. , 2016, Cancer genomics & proteomics.

[17]  A. Moustakas,et al.  Transforming growth factor β as regulator of cancer stemness and metastasis , 2016, British Journal of Cancer.

[18]  D. Tang,et al.  Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis , 2016, Hepatology.

[19]  B. Lim,et al.  Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression , 2016, Nature Communications.

[20]  B. Chauffert,et al.  Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib , 2016, Molecular Cancer.

[21]  C. Heeschen,et al.  Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation , 2015, Stem cells.

[22]  A. van Maanen,et al.  Role of Activin A and myostatin in human cancer cachexia. , 2015, The Journal of clinical endocrinology and metabolism.

[23]  C. Rice,et al.  The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. , 2015, Immunity.

[24]  S. Bekiranov,et al.  Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer. , 2015, Cancer research.

[25]  C. Andl,et al.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion , 2014, Cancers.

[26]  M. Zalewska,et al.  The role of metallothionein interactions with other proteins , 2014, Proteomics.

[27]  T. Hornberger.  Faculty Opinions recommendation of Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. , 2014 .

[28]  M. Bianchini,et al.  Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy , 2014, Molecular Cancer Therapeutics.

[29]  I. Herr,et al.  Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation , 2013, International journal of cancer.

[30]  S. Gangopadhyay.  Systemic administration of Follistatin288 increases muscle mass and reduces fat accumulation in mice , 2013, Scientific Reports.

[31]  Juan Han,et al.  Promoter methylation profiles between human lung adenocarcinoma multidrug resistant A549/cisplatin (A549/DDP) cells and its progenitor A549 cells. , 2013, Biological & pharmaceutical bulletin.

[32]  Manuel Hidalgo,et al.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. , 2011, Cell stem cell.

[33]  Tsonwin Hai,et al.  Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes. , 2010, Cancer research.

[34]  T. Zimmers,et al.  Regulation of muscle mass by follistatin and activins. , 2010, Molecular endocrinology.

[35]  J. D'haese,et al.  Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. , 2009, Gastroenterology.

[36]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[37]  C. Bianco,et al.  Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. , 2008, Cellular signalling.

[38]  J. Saklatvala,et al.  Activin A is an anticatabolic autocrine cytokine in articular cartilage whose production is controlled by fibroblast growth factor 2 and NF-kappaB. , 2007, Arthritis and rheumatism.

[39]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[40]  C. Robinson,et al.  Structural basis for the inhibition of activin signalling by follistatin , 2006, The EMBO journal.

[41]  A. Roberts,et al.  SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. , 2004, Molecular pharmacology.

[42]  R. Schmid,et al.  Genetic alterations in pancreatic carcinoma , 2003, Molecular Cancer.

[43]  G. Lees,et al.  Zinc Metabolism in the Brain: Relevance to Human Neurodegenerative Disorders , 1997, Neurobiology of Disease.

[44]  K. Titani,et al.  Activin-binding protein from rat ovary is follistatin. , 1990, Science.

[45]  G. Su,et al.  Development of orthotopic pancreatic tumor mouse models. , 2013, Methods in molecular biology.

[46]  Leonard Buckbinder,et al.  NF-kappaB RelA phosphorylation regulates RelA acetylation. , 2005, Molecular and cellular biology.

[47]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.